```
L1              STRUCTURE UPLOADED
L2           50 S L1 SSS SAM
L3        25806 S L1 SSS FULL

     FILE 'REGISTRY' ENTERED AT 10:20:21 ON 14 SEP 2010
L4              STRUCTURE UPLOADED
L5           50 S L4 SSS SAM
L6        25058 S L4 SSS FULL
L7              STRUCTURE UPLOADED

L7      STRUCTURE UPLOADED

=> d l7
L7 HAS NO ANSWERS
L7              STR
```




```
 G1 O,S


L8            0 S L7 SSS SAM
L9            3 S L7 SSS FULL

     FILE 'CAPLUS' ENTERED AT 10:22:29 ON 14 SEP 2010
L10           3 S L9
L11           3 S L10 AND (PY<=2004 OR PRY<=2004 OR AY<=2004)

     FILE 'REGISTRY' ENTERED AT 10:24:30 ON 14 SEP 2010
L12             STRUCTURE UPLOADED


L12     STRUCTURE UPLOADED

=> d l12
L12 HAS NO ANSWERS
L12             STR
```



G1 O,S

L13 0 S L12 SSS SAM
L14 32 S L12 SSS FULL

FILE 'CAPLUS' ENTERED AT 10:25:00 ON 14 SEP 2010
L15 11 S L14
L16 9 S L15 AND (PY<=2004 OR PRY<=2004 OR AY<=2004)

L16 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2010 ACS on STN
GI



I



I

AB Title compds. I [R1 = H, (un)substituted-alkyl, -cycloalkyl, etc.; R2 = H, (un)substituted-alkyl, -heterocyclyl, -aryl, etc.; R3 = H, CN, CO2H, (un)substituted alkyl or ester], and their pharmaceutically acceptable salts, are prepared and disclosed as antagonists of CGRP receptors. Thus, e.g., II was prepared by acylation of (3R,6S)-3-amino-1-(2-methoxyethyl)-6-phenylazepan-2-one (preparation given) with 4-nitrophenylchloroformate and subsequent amidation with 2-oxo-1-piperidinium-4-yl-2,3-dihydro-

1H-imidazo[4,5-b]pyridin-4-ium dichloride. I are useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. I possessed Ki or IC50 values of less than about 50 μM in CGRP receptor antagonist assays. The invention is also directed to pharmaceutical compns. comprising these compds. and the use of these compds. and compns. in the prevention or treatment of such diseases in which CGRP is involved.

ACCESSION NUMBER: 2004:902378 CAPLUS Full-text
DOCUMENT NUMBER: 141:379817
TITLE: Preparation of piperidine derivatives as CGRP receptor antagonists
INVENTOR(S): Burgey, Christopher S.; Deng, Zhengwu J.; Nguyen, Diem N.; Paone, Daniel V.; Shaw, Anthony W.; Williams, Theresa M.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004092168	A1	20041028	WO 2004-US11280	20040409 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
BR 2004009601	A	20060418	BR 2004-9601	20040409 <--
CN 1802376	A	20060712	CN 2004-80016115	20040409 <--
CN 100384843	C	20080430		

RU 2308458 C2 20071020 RU 2005-135440
20040409 <--
NZ 543357 A 20080829 NZ 2004-543357
20040409 <--
AT 413400 T 20081115 AT 2004-749887
20040409 <--
PT 1638969 E 20090116 PT 2004-749887
20040409 <--
ES 2314417 T3 20090316 ES 2004-749887
20040409 <--
EP 2039694 A1 20090325 EP 2008-105721
20040409 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR,
HU, IE,
IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LT, LV
TW 314931 B 20090921 TW 2004-93110393
20040414 <--
ZA 2005007797 A 20070228 ZA 2005-7797
20050927 <--
IN 2005DN04609 A 20070817 IN 2005-DN4609
20051010 <--
IN 224358 A1 20081031
MX 2005011166 A 20051214 MX 2005-11166
20051014 <--
KR 769030 B1 20071022 KR 2005-719692
20051014 <--
NO 2005005375 A 20051114 NO 2005-5375
20051114 <--
NO 327655 B1 20090907
HK 1090922 A1 20090612 HK 2006-111605
20061020 <--
PRIORITY APPLN. INFO.: US 2003-463089P P
20030415 <--
US 2003-510352P P
20031010 <--
EP 2004-749887 A3
20040409 <--
WO 2004-US11280 W
20040409 <--
OTHER SOURCE(S): MARPAT 141:379817
IT 781648-89-3P 781649-41-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation);
USES
(Uses)
(drug candidate; preparation of heterocyclic piperidine derivs.
as CGRP
receptor antagonists)
RN 781648-89-3 CAPLUS
CN 1-Piperidinecarboxamide, N-[(3R,6S)-1-(cyanomethyl)hexahydro-2-
oxo-6-
phenyl-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-
b]pyridin-1-yl)-
(CA INDEX NAME)

Absolute stereochemistry.



RN 781649-41-0 CAPLUS
CN 1-Piperidinecarboxamide, N-[1-(cyanomethyl)hexahydro-2-oxo-6-phenyl-1H-
azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-(CA
INDEX NAME)



IT 781650-14-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(intermediate; preparation of heterocyclic piperidine derivs. as CGRP
receptor antagonists)
RN 781650-14-4 CAPLUS
CN 1H-Azepine-1-acetonitrile, 3-aminohexahydro-2-oxo-6-phenyl-, (3R,6S)- (CA
INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2010 ACS on STN

GI



I



II

AB The present invention relates to novel heterocyclic compds. that inhibit phosphodiesterase type 4 (PDE 4). The compds. are useful for treating inflammatory conditions, diseases of the central nervous systems and insulin resistant diabetes. Title compds. I [wherein R1 = independently H, (un)substituted alk(en/yn)yl, cyclo/cycloalkyl/aryl/heterocyclyl/heteroaryl/alkyl, cycloalkenyl, aryl, heterocyclyl, etc.; P = a bond, O, S, NR1; P1 = H, halo, OR1, S(:O)R1, C(:O)R1, NO2, etc.; R2 = H, halo, (un)substituted cyclo/alkyl, CN, CH:CH2 and derivs., OH and derivs., CO2H and derivs., etc.; A = (un)substituted aryl, saturated or unsatd. 5-7 membered heterocycle; and their analogs, tautomers, regioisomers, diastereoisomers, stereoisomers, geometrical isomers, N-oxides, polymorphs, and their pharmaceutically acceptable salts and pharmaceutically acceptable solvates] were prepared as phosphodiesterase type 4 (PDE4) inhibitors for treating inflammatory and allergic disorders (no data). For example, II was prepd via acylation of (3S)-3-aminoazolane-2,5-dione (preparation given) with 3-cyclopentyloxy-4-methoxybenzoyl chloride (preparation given), and alkylation of azolane intermediate with cyclopropylmethyl bromide in the presence of CsOH. I were found excellent PDE4 inhibitors in an in vitro study against human PDE4 enzyme (no data). I and their formulations are useful for the treatment of inflammatory allergic diseases, in particular bronchial asthma, allergic rhinitis and nephritis, as well as of diseases of the central nervous system and insulin resistant diabetes (no data).

ACCESSION NUMBER: 2004:220313 CAPLUS Full-text
DOCUMENT NUMBER: 140:270743
TITLE: Preparation of heterocyclic amides, in particular azolanes and pyridines as Phosphodiesterase IV (PDE4) inhibitors for the treatment of inflammatory

and
allergic disorders
INVENTOR(S): Thomas, Abraham; Bhavar, Prashant Kashinath; Lingam,
V. S. Prasada Rao; Joshi, Neelima Kairatkar
PATENT ASSIGNEE(S): Glenmark Pharmaceuticals Limited, India
SOURCE: PCT Int. Appl., 142 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004022536	A1	20040318	WO 2003-IB3721	20030903 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
IN 2002MU00804	A	20050121	IN 2002-MU804	20020904 <--
AU 2003263393	A1	20040329	AU 2003-263393	20030903 <--

PRIORITY APPLN. INFO.: IN 2002-MU804 A 20020904 <--
WO 2003-IB3721 W 20030903 <--
OTHER SOURCE(S): MARPAT 140:270743
IT 672883-36-2P, (3S)-1-Cyanomethyl-3-[(3-cyclopentyloxy-4-methoxyphenylcarbonyl)amino]-2,5-dioxoazolane
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(Phosphodiesterase IV inhibitor; preparation of heterocyclic amides, in
particular azolanes and pyridines, as Phosphodiesterase IV (PDE4)

inhibitors for treatment of inflammatory and allergic disorders)
RN 672883-36-2 CAPLUS
CN Benzamide, N-[(3S)-1-(cyanomethyl)-2,5-dioxo-3-pyrrolidinyl]-3-(cyclopentyloxy)-4-methoxy- (CA INDEX NAME)

Absolute stereochemistry.



IT 672883-17-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(intermediate; preparation of heterocyclic amides, in particular azolanes
and pyridines, as Phosphodiesterase IV (PDE4) inhibitors for treatment
of inflammatory and allergic disorders)
RN 672883-17-9 CAPLUS
CN Carbamic acid, [(3S)-1-(cyanomethyl)-2,5-dioxo-3-pyrrolidinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 672883-37-3, (3S)-3-Amino-1-cyanomethylazolane-2,5-dione
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of heterocyclic amides, in particular azolanes and pyridines,
as Phosphodiesterase IV (PDE4) inhibitors for treatment of inflammatory
and allergic disorders)
RN 672883-37-3 CAPLUS
CN 1-Pyrrolidineacetonitrile, 3-amino-2,5-dioxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



FILE 'REGISTRY' ENTERED AT 10:28:16 ON 14 SEP 2010
L17 STRUCTURE UPLOADED

L17 STRUCTURE UPLOADED

=> d l17
L17 HAS NO ANSWERS
L17 STR



G1 O,S

L18 1 S L17 SSS SAM
L19 6 S L17 SSS FULL

FILE 'CAPLUS' ENTERED AT 10:28:50 ON 14 SEP 2010
L20 2 S L19
L21 2 S L20 AND (PY<=2004 OR PRY<=2004 OR AY<=2004)

L21 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2010 ACS on STN
GI



I

AB A rapid structure-activity study was performed by parallel liquid synthesis on N,N'-disubstitution of 3-aminoazepin-2-one to afford potent and specific farnesyl transferase inhibitors with low nM

enzymic and cellular activities. The activities of the selected compds. were validated in vivo, and compds. I (R = 2-Cl, 3-Br) presented significant antitumor activity.

ACCESSION NUMBER: 2003:462563 CAPLUS Full-text
DOCUMENT NUMBER: 140:42082
TITLE: Parallel liquid synthesis of N,N'-disubstituted 3-aminoazepin-2-ones as potent and specific farnesyl transferase inhibitors
AUTHOR(S): Le Diguarher, Thierry; Ortuno, Jean-Claude; Dorey, Gilbert; Shanks, David; Guilbaud, Nicolas; Pierre, Alain; Fauchere, Jean-Luc; Hickman, John A.; Tucker, Gordon C.; Casara, Patrick J.
CORPORATE SOURCE: Department of Medicinal Chemistry, Institut de Recherches Servier, Croissy sur Seine, 78290, Fr.
SOURCE: Bioorganic & Medicinal Chemistry (2003), 11(14), 3193-3204
CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 140:42082

IT 635753-78-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(N,N'-disubstituted 3-aminoazepin-2-ones as farnesyl transferase inhibitors)

RN 635753-78-5 CAPLUS
CN Benzonitrile, 4-[[5-[[[hexahydro-2-oxo-1-[(phenylsulfonyl)methyl]-1H-azepin-3-yl]amino]methyl]-1H-imidazol-1-yl]methyl]-, hydrochloride (1:2)
(CA INDEX NAME)



●2 HCl

IT 635754-80-2P 635754-85-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(N,N'-disubstituted 3-aminoazepin-2-ones as farnesyl transferase
inhibitors)
RN 635754-80-2 CAPLUS
CN Carbamic acid, [hexahydro-2-oxo-1-[(phenylsulfonyl)methyl]-1H-azepin-3-yl]-
, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 635754-85-7 CAPLUS
CN 2H-Azepin-2-one, 3-aminohexahydro-1-[(phenylsulfonyl)methyl]- (CA INDEX
NAME)



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD
(7 CITINGS)
REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2010 ACS on STN
GI



I



II

AB Title compds. I [W = CO, CH2; X = bond, alkylene, CO, S(O)n, S(O)nA1, COA1, A1S(O)nA2, A1COA2; Y = (un)substituted aryl, heteroaryl, cycloalkyl, heterocyclalkyl; T = NR1, NR1CO; V = H, (un)substituted aryl, heteroaryl; A1, A2 = alkylene; A3 = (CR2R3)p; R1-R3 = H, (un)substituted alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl; n = 0-2; p = 0-4] were prepared for use as farnesyl transferase inhibitors in the treatment of cancers, neurofibromatosis type 1, and restenosis after angioplasty or vascular surgery. Thus, (S)-3-amino-1-benzyl-2-azepanone was prepared from L-lysine in 4 steps and treated with 1-(4-cyanobenzyl)-1H-imidazole-5- carboxaldehyde, obtained by treating HOCH2COCH2OH with PhCH2NH2 and KSCN and oxidation of the resulting alc., to give the title compound II.

ACCESSION NUMBER: 2002:555454 CAPLUS Full-text
DOCUMENT NUMBER: 137:125097
TITLE: Novel azepanes as farnesyl transferase inhibitors
INVENTOR(S): Casara, Patrick; Le Diguarher, Thierry; Dorey, Gilbert; Hickman, John; Pierre, Alain; Tucker, Gordon; Guilbaud, Nicolas; Ortuno, Jean-Claude; Fauchere, Jean-Luc
PATENT ASSIGNEE(S): Les Laboratoires Servier, Fr.
SOURCE: PCT Int. Appl., 78 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002057223	A2	20020725	WO 2002-FR147	20020116 <--
WO 2002057223	A3	20021128		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE, TR

FR 2819511 A1 20020719 FR 2001-638 20010118 <--

AU 2002231886 A1 20020730 AU 2002-231886 20020116 <--

PRIORITY APPLN. INFO.: FR 2001-638 A 20010118 <--

WO 2002-FR147 W 20020116 <--

OTHER SOURCE(S): MARPAT 137:125097

IT 443920-50-1P 443920-51-2P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(novel azepanes as farnesyl transferase inhibitors)

RN 443920-50-1 CAPLUS

CN Benzonitrile, 4-[[5-[[[(3S)-hexahydro-2-oxo-1-[(phenylsulfonyl)methyl]-1H-azepin-3-yl]amino]methyl]-1H-imidazol-1-yl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 443920-51-2 CAPLUS

CN Benzonitrile, 4-[[5-[[[(3S)-hexahydro-2-oxo-1-[(phenylsulfonyl)methyl]-1H-azepin-3-yl]amino]methyl]-1H-imidazol-1-yl]methyl]-, hydrochloride (1:2)

(CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

FILE 'REGISTRY' ENTERED AT 10:30:00 ON 14 SEP 2010
L22 STRUCTURE UPLOADED

L22 STRUCTURE UPLOADED

=> d l22
L22 HAS NO ANSWERS
L22 STR



G1 O,S

L23 0 S L22 SSS SAM
L24 4 S L22 SSS FULL

FILE 'CAPLUS' ENTERED AT 10:30:31 ON 14 SEP 2010
L25 1 S L24

L25 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2010 ACS on STN
AB The epimerization-free synthesis and characterization of a class of conformational constrained lactam aminoboronic acid inhibitors of dipeptidyl peptidase IV (DPP IV; E.C. 3.4.14.5) is described. These compds. have the advantage that they cannot undergo the pH-dependent cyclization prevalent in most dipeptidyl boronic acids that attenuates their potency at physiol. pH. For example, D-3-amino-1-[L-1-boronic-ethyl]-pyrrolidine-2-one (amino-D-lactam-L-boroAla), one of the best lactam inhibitors of DPP IV, is several orders of magnitude less potent than L-Ala-L-boroPro, as measured by Ki values (2.3 nM vs 30 pM, resp.). At physiol. pH, however, it is actually more potent than L-Ala-L-boroPro, as measured by IC50 values (4.2 nM vs 1400 nM), owing to the absence of the potency-attenuating cyclization. In an interesting and at first

sight surprising reversal of the relationship between stereochem. and potency observed with the conformational unrestrained Xaa-boroPro class of inhibitors, the L-L diastereomers of the lactams are orders of magnitude less effective than the D-L lactams. However, this interesting reversal and the unexpected potency of the D-L lactams as DPP IV inhibitors can be understood in structural terms, which is explained and discussed here.

ACCESSION NUMBER: 2007:454223 CAPLUS Full-text
DOCUMENT NUMBER: 147:95888
TITLE: Synthesis and characterization of constrained peptidomimetic dipeptidyl peptidase IV inhibitors: amino-lactam boroalanines
AUTHOR(S): Lai, Jack H.; Wu, Wengen; Zhou, Yuhong; Maw, Hlaing H.; Liu, Yuxin; Milo, Lawrence J., Jr.; Poplawski, Sarah E.; Henry, Gillian D.; Sudmeier, James L.; Sanford, David G.; Bachovchin, William W.
CORPORATE SOURCE: Department of Biochemistry, Tufts University School of Medicine, Boston, MA, 02111, USA
SOURCE: Journal of Medicinal Chemistry (2007), 50(10), 2391-2398
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 147:95888

IT 942216-61-7P 942216-62-8P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and computational study of peptidomimetics starting from methionine and homoserine derivs. via coupling with boroamino acid derivs. as key step, and their antidiabetic activity as dipeptidyl peptidase IV inhibitor)

RN 942216-61-7 CAPLUS
CN Boronic acid, B-[(1R)-1-[(3R)-3-amino-2-oxo-1-pyrrolidinyl]ethyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 942216-62-8 CAPLUS
CN Boronic acid, B-[(1R)-1-[(3S)-3-amino-2-oxo-1-pyrrolidinyl]ethyl]-
,
hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

FILE 'REGISTRY' ENTERED AT 10:31:37 ON 14 SEP 2010
L26 STRUCTURE UPLOADED

L26 STRUCTURE UPLOADED

=> d l26
L26 HAS NO ANSWERS
L26 STR



G1 O,S

L27 0 S L26 SSS SAM

L28 0 S L26 SSS FULL
L29 STRUCTURE UPLOADED

L29 STRUCTURE UPLOADED

=> d l29
L29 HAS NO ANSWERS
L29 STR



G1 O,S

L30 0 S L29 SSS SAM
L31 0 S L29 SSS FULL